Menu
Menu
Thermaiscan
Developing breast cancer pre-screening solution based on AI, combined with existing thermal sensors in standard smartphones
- AI, Female Founder, Healthtech
- Seed
Location
Stockholm, Sweden
Revenue size
0 (pre-revenue)
Year founded
2019
Funding raised
None
Founders
Armen Aghinyan, Arby Leonian, Katarina Eriksson, Areg Gevorgyan Fredrik Sandholm, Nerses Berberian, Piotr Pietrzak, Tigran Vardanyan, Varduhi Shahinyan
Most relevant investors
Bootstrapping
Team size
10+
Problem
Late detection of breast cancer is a growing global problem, and the cause of 70% of all breast cancer deaths in low- and middle income countries. Many women have little or no access to specialists for ultrasound and mammography, or are not able to pay the fee.
SOLUTION
Thermaiscan has developed an affordable pocket-sized, AI-enhanced and non-invasive solution that non-specialist healthcare personnel can use to screen symptomatic and asymptomatic patients for breast cancer.
Thermaiscan AI analyzes smartphone thermal images on pixel level, and can identify early and small anomalous metabolism in the chest, invisible to the human eye. These changes might not even be known by the patient and can be early stages of breast cancer development. The solution acts as a complement to existing breast cancer screening tools, and is designed for the first line of healthcare. If there is any risk detected by the AI, the patient is recommended to meet a specialist.
KEY CUSTOMERS AND INTERNATIONAL PRESENCE
Mini-clinics, primary care, mother-and child care, remote units and hospitals. Thermaiscan has clinically validated the solution in Armenia and is preparing clinical validations in Singapore and India.
Team
Thermaiscan core team was founded in 2019 and contains in-house specialists covering areas of expertise in AI, thermal technology, breast cancer, communication & product development that still several years later passionately work together unpaid to make an impact.
Unique selling point
Easy-to-use smartphone based thermal pre-screening for nurses, making it possible for women at all ages, and for those with dense breast tissue, to easier understand their chest health and possibly find signs of breast cancer development in early stages in a comfortable and affordable way.
Asia Connection
Thermaiscan is part of India-Sweden Healthcare Innovation center since 2021 and has LOI’s with hospitals and a mother- and child primary care. In Singapore, Thermaiscan has signed an MoU with AstraZeneca, and will soon initiate clinical trials with major public healthcare actors. They expect first sales in Singapore in Q4 2024.
Pitch
